BU-NOT-SET
Global contract development and manufacturing organisation (CDMO) Recipharm has today announced the appointment of Vikas Gupta as President of its recently renamed biologics business unit, ReciBioPharm.
Vikas joins ReciBioPharm from Repligen Corporation, where he was Vice President & General Manager, Gene Therapy and Downstream Bioprocessing, and brings over 20 years’ experience in life sciences to the business unit.
This appointment comes as Recipharm officially renames its biologics business unit following the acquisitions of advanced therapy CDMO, Arranta Bio; GenIbet, a specialist in the manufacture of biological clinical material; and virotherapy CDMO, Vibalogics.
Commenting on his appointment, Vikas Gupta said: “As President of ReciBioPharm, I will lead the team as we continue to support innovative biotechs advancing their therapies and bringing their drug products to market.
With such a wealth of expertise and breadth of services now combined under one name, backed by the strength of the Recipharm Group, we offer a very compelling proposition for the biologics market. I look forward to helping promote this full service offering to our customers and prospects.”
Marc Funk, CEO, Recipharm said: “Vikas has a wealth of experience in the biologics sector and he’s the perfect candidate to drive the success of our ReciBioPharm business unit.
The name ReciBioPharm places ‘Bio’ at the centre of our brand. This reflects the importance of our biologics offering to the whole Recipharm Group.
This is an exciting time for our organisation and our customers can expect to see many new developments as ReciBioPharm continues to grow and evolve.”
Arranta Bio, GenIbet and Vibalogics bring established specialisms to ReciBioPharm. The business unit is well placed to offer capabilities in innovative technologies across gene therapy, viral vectors, mRNA, pDNA, oncolytic viruses and microbiome.
Contact information
For media enquiries, please contact Fiona Whyatt at ramarketing PR, [email protected], +44 (0)191 222 1242
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.
For more information on Recipharm and our services, please visit www.recipharm.com